New drug combo aims to stop deadly lung Cancer's comeback
NCT ID NCT07431827
Summary
This study is testing whether adding a new targeted drug (MK-1084) to an existing immunotherapy helps prevent lung cancer from returning after surgery. It's for people with a specific genetic mutation (KRAS G12C) whose cancer was removed but has a high risk of coming back. The main goal is to see if this combination keeps people cancer-free longer compared to the standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lviv Territorial Medical Union Multidisciplinary Clinical Hospital
RECRUITINGLviv, 79059, Ukraine
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.